Pfizer-Valneva Lyme vaccine pact sees HSR clearance
Under the terms of the Agreement, Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of $308 million cash payments consisting of the $130 million upfront payment described above, $35 million in development milestones and $143 million in early commercialization milestones
France: Valneva SE has announced that the antitrust-related condition precedent for its Lyme vaccine collaboration agreement with Pfizer has been met. As a result, the Agreement is now effective and Valneva will receive a $130 million upfront payment.
Valneva and Pfizer announced their collaboration at the end of April 2020 to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.
Following the execution of the Agreement, Pfizer and Valneva notified the US Federal Trade Commission and the Antitrust Division of the Department of Justice in accordance with applicable antitrust law including the Hart Scott Rodino Antitrust Improvements Act.
Under the terms of the Agreement, Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of $308 million cash payments consisting of the $130 million upfront payment described above, $35 million in development milestones and $143 million in early commercialization milestones. Valneva will fund 30% of all development costs through completion of the development program, and in return, Pfizer will pay Valneva tiered royalties starting at 19%. Pfizer will lead to late-stage development and have sole control over commercialization.
VLA15 is the only active Lyme disease vaccine program in clinical development today and covers six serotypes that are prevalent in North America and Europe. The program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 20171. Valneva has completed patient enrolment and follow-up for VLA15's two Phase 2 studies in more than 800 people and expects to report the first Phase 2 results in July 2020.
Lyme disease is a systemic infection caused by Borrelia bacteria transmitted to humans by infected Ixodes ticks. It is considered the most common vector borne illness in the Northern Hemisphere.
Read also: Pfizer to infuse up to USD 500 million in public drug developers
